Targeted massively parallel sequencing in the management of evaluated as cytogenetically normal lymphoid malignancies

Basit Öğe Kaydı
dc.authorscopusid56429434500
dc.authorscopusid54887131700
dc.authorscopusid57193613398
dc.authorscopusid56472783500
dc.authorscopusid14037106700
dc.authorscopusid57159874200
dc.authorscopusid56429431400
dc.contributor.authorAtli E.I.
dc.contributor.authorGurkan H.
dc.contributor.authorAtli E.
dc.contributor.authorYalcintepe S.
dc.contributor.authorDemir S.
dc.contributor.authorEker D.
dc.contributor.authorKalkan R.
dc.date.accessioned2024-06-12T10:28:26Z
dc.date.available2024-06-12T10:28:26Z
dc.date.issued2021
dc.description.abstractThe variations in clinical and biological background of lymphoid malignancies trigger researchers to try to find out novel therapeutic targets. A typical treatment includes multiagent chemotherapy and/or targeted therapy in the light of driver mutations. Next generation sequencing (NGS) plays a pivotal role during the identification of genetic alterations in lymphoid malignancies. A total of 52 patients [30 men (58%) and 22 women (42%)] having normal cytogenetic and FISH results were enrolled in this study. Usage of NGS based targeted sequencing can confirm or support a particularly preferred diagnosis (41/52, 78%) or make a differential diagnosis in cases of interference. Notably, in 11 out of these 52 cases (21%), the initial suspect diagnosis was not supported by the NGS result and thereby had to be reconsidered. In this study, we highlight the importance of targeted NGS panel testing for diagnosis, prognosis and treatment decision in highly selected instances of lymphoid malignancies and lymphoproliferative disorders in which histopathology and more conventional molecular analyses remain inconclusive. © 2021 Zerbinis Publications. All rights reserved.en_US
dc.identifier.endpage1548en_US
dc.identifier.issn1107-0625
dc.identifier.issue4en_US
dc.identifier.pmid34565017en_US
dc.identifier.scopus2-s2.0-85114510268en_US
dc.identifier.scopusqualityQ3en_US
dc.identifier.startpage1540en_US
dc.identifier.urihttps://hdl.handle.net/20.500.14551/17254
dc.identifier.volume26en_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherZerbinis Publicationsen_US
dc.relation.ispartofJournal of B.U.ON.en_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectLymphoid Malignancies; Ngs; Targeted Therapyen_US
dc.subjectAtm Protein; Azacitidine; Bendamustine; Bevacizumab; Bloom Syndrome Helicase; Brca2 Protein; Calreticulin; Cd135 Antigen; Checkpoint Kinase 2; Cyclin Dependent Kinase Inhibitor 2a; Cyclophosphamide; Cyclophosphamide Plus Doxorubicin Plus Prednisolone Plus Rituximab Plus Vincristine; Dasatinib; Decitabine; E1a Associated P300 Protein; Everolimus; F Box/Wd Repeat Containing Protein 7; Gamma Secretase Inhibitor; Glucocorticoid; Interleukin 7 Receptor; Janus Kinase 1; Janus Kinase Inhibitor; Lenalidomide; Mitoxantrone; Notch1 Receptor; Olaparib; Palbociclib; Pazopanib; Phf6 Protein; Pladienolide; Prednisolone; Protein P53; Rituximab; Ruxolitinib; Selinexor; Sorafenib; Srsf2 Protein; Stag2 Protein; Sunitinib; Telomerase Reverse Transcriptase; Temsirolimus; Tet2 Protein; Tofacitinib; Trametinib; Tuba3c Protein; Unclassified Drug; Acute Lymphoblastic Leukemia; Adult; Amplicon; Article; Cancer Combination Chemotherapy; Cancer Diagnosis; Cancer Prognosis; Cancer Therapy; Chronic Lymphatic Leukemia; Clinical Decision Making; Cytogenetics; Differential Diagnosis; Diffuse Large B Cell Lymphoma; Female; Fluorescence In Situ Hybridization; Follow Up; Gene Frequency; Genetic Variability; Genetic Variation; High Throughput Sequencing; Histopathology; Hodgkin Disease; Human; Indel Mutation; Karyotype; Lymphoma; Lymphoproliferative Disease; Major Clinical Study; Male; Marginal Zone Lymphoma; Missense Mutation; Molecularly Targeted Therapy; Nonhodgkin Lymphoma; Oncogene N Ras; Personalized Medicine; Adolescent; Aged; Child; Chromosome Analysis; Genetics; High Throughput Sequencing; Infant; Leukemia; Lymphoma; Middle Aged; Preschool Child; Procedures; Retrospective Study; Young Adult; Adolescent; Adult; Aged; Child; Child, Preschool; Cytogenetic Analysis; Female; High-Throughput Nucleotide Sequencing; Humans; Infant; Leukemia; Lymphoma; Male; Middle Aged; Retrospective Studies; Young Adulten_US
dc.titleTargeted massively parallel sequencing in the management of evaluated as cytogenetically normal lymphoid malignanciesen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

Scopus İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu